About PhilVE

View Dashboard

The Philippine Vaccine Effectiveness Study (PhilVE) is the inaugural under the Program for Research on Emerging Infectious Diseases (PREID). PhilVE estimates the effectiveness of the COVID-19 vaccines used in the Philippines by immunogenicity and prevention of symptomatic COVID-19. Twelve cohort sites, where the National COVID-19 Vaccination Program was rolled out, were engaged for 12 months for this research.

The PhilVE study is conducted under the University of the Philippines Manila through the National Institutes of Health – Institute of Clinical Epidemiology (ICE) and is funded by the Department of Science and Technology – Philippine Council for Health Research and Development (DOST-PCHRD).

PhilVE Objectives

Objective 1

Determine the specific IgG to SARS-CoV-2 levels obtained at 2, 12, 24, 36, and 52 weeks after the second dose among adults who received any of the EUA-approved COVID-19 vaccines.

Objective 2

Compare the IgG levels obtained at 2, 12, 24, 36, and 52 weeks after second dose according to type of vaccine received, age, sex, comorbidities.

Objective 3

Describe the COVID-19 infections over a 12-month period from the second dose of COVID-19 vaccines which will occur among vaccinated and unvaccinated individuals within the clusters including identification of variants of concern as the etiologies of such post vaccination COVID-19 infections.

Why the PhilVE Study Matters

The Philippine Vaccine Effectiveness (PhilVE) project aims to shed light on knowledge gaps concerning the development of antibodies after vaccination, the meaning of antibody response to protection against both symptomatic and asymptomatic infections, the effectiveness of the vaccines against variants of the SARS-CoV2 as well as duration of protection.

This study may enable us to close the knowledge gap on:

  • Antibody immune response from vaccination
  • Understanding detection and recognition of antibody adaptive immune responses after vaccination
  • Population and individual variations in immune response which affect vaccine effectiveness in different subgroups defined by factors such as age, sex, comorbidities
  • Determine duration of protection through serial antibody testing
  • Early recognition of emergence of new coronavirus strains among those vaccinated.
External Links
COVID Vaccine Effectiveness Resources
  • For Medical Professionals & Researchers
  • For Policymakers
  • For Business Owners
  • For Barangay Health Workers
  • Glossary/ Definition of Terms

Team Members

Regina P. Berba, MD, MSc
Principal Investigator
Eva Maria Cutiongco-de la Paz, MD
Co-Investigator
Marissa M. Alejandria, MD, MSc
Co-Investigator
National Coordinating Team
Project Management
  • Arturo M. Ongkeko Jr.
  • Rona May de Vera
  • Maritess Nepomuceno
Health Informatics & Data Management Team
  • Dr. Raymond Francis Sarmiento
  • Manuel O. Gaspar
  • Peter Lazo
  • Terrence Mendoza
  • Joshua Lazo
  • Juvar Abrera
Statistical Analysis Team
  • Dr. Kim Cochon
  • Dr. Amiel Bermudez
  • Juztin del Rosario
  • Marla Briones
Communications Team
  • Jean Francis Barcena
  • Jenny Lynn Carigma